What question did this study set out to answer?

This research aims to characterize SLC41A3 to determine its role as a prognostic biomarker and therapeutic target in hepatocellular carcinoma (HCC).

Comprehensive characterization of SLC41A3 identifies it as an immune-related prognostic biomarker and therapeutic target in hepatocellular carcinoma

View Full Paper

Ask AI

Bookmark

This research aims to characterize SLC41A3 to determine its role as a prognostic biomarker and therapeutic target in hepatocellular carcinoma (HCC).
Screened differentially expressed SLC genes from the TCGA-LIHC cohort.
Constructed diagnostic and prognostic models using machine learning and LASSO regression.
Validated SLC41A3's biological function through in vitro assays and in vivo xenograft models.
Identified 69 differentially expressed SLC genes in HCC, with eight being independent prognostic factors, including SLC41A3.
High SLC41A3 expression correlates with poorer patient survival and altered immune cell infiltration.
Knockdown of SLC41A3 inhibited HCC cell proliferation, migration, and invasion in vitro, and reduced tumor growth in vivo.

No takes yet. Share an insight, caveat, or question.

Randomized trial identifies SLC41A3's role as a prognostic biomarker in HCC, suggesting it as a therapeutic target.

Gong et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark